A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI 571, Glivec).
Drummond
A
A
Micallef-Eynaud
P
P
Douglas
W S
WS
Hay
I
I
Holyoake
T L
TL
Drummond
M W
MW
D000970:Antineoplastic Agents / Q000009:adverse effects*; D001549:Benzamides; D015331:Cohort Studies; D003875:Drug Eruptions / Q000209:etiology*; D004791:Enzyme Inhibitors / Q000009:adverse effects*; D005500:Follow-Up Studies; D006801:Humans; D000068877:Imatinib Mesylate; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy*; D010879:Piperazines / Q000009:adverse effects*; D011446:Prospective Studies; D011743:Pyrimidines / Q000009:adverse effects*
D000970:Antineoplastic Agents; D001549:Benzamides; D004791:Enzyme Inhibitors; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate